Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01)

叶黄素 医学 吉西他滨 胰腺癌 化疗 新辅助治疗 内科学 临床终点 肿瘤科 不利影响 外科 癌症 随机对照试验 奥沙利铂 乳腺癌 结直肠癌
作者
Junpei Yamaguchi,Yukihiro Yokoyama,Tsutomu Fujii,Suguru Yamada,Hideki Takami,Hiroki Kawashima,Eizaburo Ohno,Takuya Ishikawa,Osamu Maeda,Hiroshi Ogawa,Yasuhiro Kodera,Masato Nagino,Tomoki Ebata
出处
期刊:Annals of Surgery [Lippincott Williams & Wilkins]
卷期号:275 (6): 1043-1049 被引量:67
标识
DOI:10.1097/sla.0000000000005430
摘要

Objective: Given the frequent adverse events with multidrug chemotherapy, not only the survival benefit but also the feasibility of using neoadjuvant chemotherapy to treat pancreatic cancer need to be clarified. Summary of Background Data: Although the development of multidrug chemotherapy regimens has improved the survival outcomes of patients with unresectable pancreatic cancer, the benefits of these treatments in the neo-adjuvant setting remain controversial. Methods: Patients with borderline-resectable pancreatic cancer were enrolled and randomly assigned to receive neoadjuvant chemotherapy with either FOLFIRINOX or gemcitabine with nab-paclitaxel (GEM/nab-PTX). After the completion of chemotherapy, patients underwent surgical resection when feasible. This study (NUPAT-01) was a randomized phase II trial, and the primary endpoint was the R0 resection rate. Results: Fifty-one patients were enrolled in this study [FOLFIRINOX (n = 26) and GEM/nab-PTX (n = 25)]. A total of 84.3% (n = 43/51) of the patients eventually underwent surgery, and R0 resection was achieved in 67.4% (n = 33/ 51) of the patients. Adverse events (grade >3) due to neoadjuvant treatment were observed in 45.1% of the patients (n = 23/51), and major surgical complications occurred in 30.0% (n = 13/43), with no mortality noted. The intention-to-treat analysis showed that the 3-year overall survival rate was 54.7%, with a median survival time of 39.4 months, and a significant difference in overall survival was not observed between the FOLFIRINOX and GEM/nab-PTX groups. Conclusions: These results indicate that neoadjuvant chemotherapy with FOLFIRINOX or GEM/nab-PTX is feasible and well tolerated, achieving an R0 resection rate of 67.4%. The survival of patients was even found to be favorable in the intention-to-treat analysis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
星辰大海应助刘鑫宇采纳,获得10
1秒前
1秒前
AireenBeryl531应助wwz采纳,获得50
1秒前
Ava应助眼睛大莆采纳,获得10
1秒前
Jasper应助kkyy采纳,获得10
2秒前
Lucas应助kkyy采纳,获得10
2秒前
Akim应助kkyy采纳,获得10
2秒前
有何丿不可应助kkyy采纳,获得10
2秒前
领导范儿应助kkyy采纳,获得10
2秒前
脑洞疼应助kkyy采纳,获得10
2秒前
李健应助kkyy采纳,获得10
2秒前
所所应助kkyy采纳,获得10
2秒前
传奇3应助kkyy采纳,获得10
3秒前
风俗店在逃男模完成签到,获得积分10
3秒前
Auston_zhong应助kkyy采纳,获得10
3秒前
周芷天完成签到,获得积分10
3秒前
刘启迪完成签到,获得积分10
3秒前
4秒前
852应助白桃枝采纳,获得10
4秒前
颜靖仇发布了新的文献求助10
5秒前
5秒前
量子星尘发布了新的文献求助10
5秒前
6秒前
万能图书馆应助眼睛大莆采纳,获得10
6秒前
6秒前
7秒前
点点完成签到,获得积分10
10秒前
顾矜应助给你吃一个屁采纳,获得10
10秒前
TIGun发布了新的文献求助10
11秒前
11秒前
11秒前
所所应助kkyy采纳,获得10
11秒前
FashionBoy应助kkyy采纳,获得10
11秒前
11秒前
桐桐应助kkyy采纳,获得10
11秒前
迟大猫应助kkyy采纳,获得10
11秒前
科研通AI5应助gbx采纳,获得30
11秒前
Bob完成签到,获得积分10
11秒前
猪猪hero发布了新的文献求助10
11秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Neuromuscular and Electrodiagnostic Medicine Board Review 1000
Statistical Methods for the Social Sciences, Global Edition, 6th edition 600
こんなに痛いのにどうして「なんでもない」と医者にいわれてしまうのでしょうか 510
Walter Gilbert: Selected Works 500
An Annotated Checklist of Dinosaur Species by Continent 500
岡本唐貴自伝的回想画集 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3658616
求助须知:如何正确求助?哪些是违规求助? 3220669
关于积分的说明 9736872
捐赠科研通 2929813
什么是DOI,文献DOI怎么找? 1604106
邀请新用户注册赠送积分活动 756967
科研通“疑难数据库(出版商)”最低求助积分说明 734269